AffyXell, Avacta’s joint venture with Daewoong Pharmaceutical, expands its manufacturing partnership with GenScript ProBio for cell therapies
Avacta Group PLC (AIM:AVCT) AffyXell expands partnership with GenScript ProBio
Genflow Biosciences Plc (LSE:GENF) Company Update
Genflow (LSE: GENF), a UK-based biotechnology company focused on longevity and the development of therapies to counteract the effects of ageing and diseases associated with advanced age, is pleased to
Abingdon Health PLC (AIM:ABDX) Strategic collaboration with Bimelix Ab
Focused on the on development and commercialisation of Lyme disease lateral flow self-test
Poolbeg Pharma PLC (AIM:POLB) GMP manufacturing contract signed
Update on POLB 001 Clinical Development
Open Orphan PLC (AIM:ORPH) Wellcome publication
Key considerations document for developing and manufacturing challenge agents published
Poolbeg Pharma PLC (AIM:POLB) Attendance at European Melioidosis Congress
Poolbeg to engage with key international stakeholders at congress as it develops an intramuscular Melioidosis vaccine candidate
Avacta Group PLC (AIM:AVCT) London Therapeutics headquarters established
Avacta establishes new Therapeutics headquarters at Scale Space, Imperial College White City Campus
Omega Diagnostics Gp (AIM:ODX) Placing, Subscription and Open Offer
Placing of 50,000,000 New Ordinary Shares and Warrants
Open Orphan PLC (AIM:ORPH) hVIVO’s first ever Phase II field study site study awarded
First site study awarded offering new site services since facilities expansion
Open Orphan PLC (AIM:ORPH) Comment re: speculation
Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, notes market
Open Orphan PLC (AIM:ORPH) Appointment of Nominated Adviser and Joint Broker
Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that
